--- title: "References for Poster - Vancouver" author: "By Emma Jansz, Guy Hammerschmidt, Taj Astill,& Reegan Chin" date: "2024-05-17" output: html_document: default pdf_document: default --- ```{r setup, include=FALSE} knitr::opts_chunk$set(echo = TRUE) ``` ## Why are they Wicked problems?: * Mental health [Internet]. [cited 2024 May 16]. Available from: https://www.who.int/health-topics/mental-health * admin. Depression Australia Statistics | Facts, Percentage & How Common [Internet]. Family Talks Clinic. 2023 [cited 2024 May 16]. Available from: https://familytalksclinic.com.au/depression-australia-statistics/ ## Serotonin Hypothesis, the HPA Axis and GABA: * Nautiyal KM, Hen R. Serotonin receptors in depression: from A to B [Internet]. F1000Research; 2017 [cited 2024 May 16]. Available from: https://f1000research.com/articles/6-123 ## Gut Health: * Herselman MF, Bailey S, Bobrovskaya L. The Effects of Stress and Diet on the "Brain-Gut" and "Gut-Brain" Pathways in Animal Models of Stress and Depression. Int J Mol Sci. 2022;23(4). * Kumar A, Pramanik J, Goyal N, Chauhan D, Sivamaruthi BS, Prajapati BG, et al. Gut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options. Pharmaceuticals (Basel). 2023;16(4). * Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut microbiota's effect on mental health: The gut-brain axis. Clin Pract. 2017;7(4):987. ## Autism: * Schuster BA, Sowden S, Rybicki AJ, Fraser DS, Press C, Holland P, et al. Dopaminergic Modulation of Dynamic Emotion Perception. J Neurosci. 2022 May 25;42(21):4394–400. * Mandic-Maravic V, Grujicic R, Milutinovic L, Munjiza-Jovanovic A, Pejovic-Milovancevic M. Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment. Front Psychiatry. 2022 Feb 3;12:787097 * Davico C, Secci I, Vendrametto V, Vitiello B. Pharmacological treatments in Autism Spectrum Disorder: a narrative review. Journal of Psychopathology [Internet]. 2023 May [cited 2024 May 17];29(1):38–52. Available from: https://doi.org/10.36148/2284-0249-N251 * Gabis LV, Gross R, Barbaro J. Editorial: personalized precision medicine in autism spectrum-related disorders. Front Neurol [Internet]. 2021 Sep 28 [cited 2024 May 17];12:730852. Available from: https://www.frontiersin.org/articles/10.3389/fneur.2021.730852/full ## Substance Abuse: * Turner S, Mota N, Bolton J, Sareen J. Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. Depress Anxiety. 2018 Sep;35(9):851–60. * Drugs, Brains, and Behavior: The Science of Addiction. Treatment and Recovery | National Institute on Drug Abuse (NIDA) [Internet]. -- [cited 2024 May 16]. Available from: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery * Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds III CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67. ## MDMA Use: * Roiser JP, Sahakian BJ. Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology. 2004 May 1;173(3):411–7. * Mustafa NS, Bakar NHA, Mohamad N, Adnan LHM, Fauzi NFAM, Thoarlim A, et al. MDMA and the Brain: A Short Review on the Role of Neurotransmitters in Neurotoxicity. Basic Clin Neurosci. 2020;11(4):381–8. * Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001 Oct 2;165(7):917–28. * de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition. Therapeutic Drug Monitoring. 2004 Apr;26(2):137. * MDMA (Ecstasy) Abuse Research Report. What are the effects of MDMA? | National Institute on Drug Abuse (NIDA) [Internet]. -- [cited 2024 May 16]. Available from: https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/what-are-effects-mdma * Dobry Y, Rice T, Sher L. Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. International Journal of Adolescent Medicine and Health. 2013 Sep 1;25(3):193–9. * O’Hearn E, Battaglia G, Souza ED, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988 Aug 1;8(8):2788–803. * Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 1987 Apr 1;241(1):338–45.

## Solutions: * Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833-43. * Sharp T, Collins H. Mechanisms of SSRI Therapy and Discontinuation. Curr Top Behav Neurosci. 2023